Clinical Trial Update: Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing telbivudine and entecavir in HBeAg-positive chronic hepatitis B completed, evaluating reduction of serum HBsAg levels.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Hepatitis D

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Telbivudine (telbivudine)

Snippet

Sponsor: Asan Medical Center | Conditions: Chronic Viral Hepatitis B Without Delta-agent | Phase 3 | Status: COMPLETED